Vaccine makers and medicine regulators are sketching out plans in case the mutating coronavirus turns vaccine development into a game of cat and mouse.
Just weeks after leading manufacturers secured the first regulatory approvals, mutations in the virus have forced scientists to re-test their Covid-19 vaccines and prepare to tweak their formula should the shots prove less effective.
At the same time, regulators are considering how they could fast-track new approvals and whether they could use the seasonal flu jab as a model to authorise revised versions without requiring long trials.
您已閱讀10%（590字），剩餘90%（5348字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。